JP Morgan Initiates Coverage On AbCellera Biologics with Overweight Rating, Announces Price Target of $17

Benzinga Newsdesk www.benzinga.com Neutral 56.1%

Neg 0% Neu 56.1% Pos 0%

JP Morgan analyst Brian Cheng initiates coverage on AbCellera Biologics (NASDAQ:ABCL) with a Overweight rating and announces Price Target of $17.